| 209 | 9 | 303 |
| 下载次数 | 被引频次 | 阅读次数 |
目的探讨192例甲状腺乳头状癌中BRAFV600E基因突变与临床病理因素的相关性;方法收集入组病例的临床病理资料,采用实时荧光定量PCR法检测192例经手术切除的甲状腺乳头状癌石蜡切片组织中BRAFV600E基因突变情况,分析BRAFV600E基因突变与临床病理因素的关系。结果 192例甲状腺乳头状癌中BRAFV600E基因突变率为85.42%(164/192),其中BRAFV600E基因在微小乳头状癌组的突变率为83.1%(108/130)、BRAFV600E在中央区淋巴结转移组突变率为92.3%(84/91)、BRAFV600E在被膜受侵组的突变率为90.00%(36/40)、BRAFV600E在多灶性组的突变率为67.57%(50/74)。BRAFV600E基因突变与微小乳头状癌、中央区淋巴结转移、被膜受侵、多灶性有统计学意义,结论 BRAFV600E基因突变与甲状腺癌预后相关,可作为判断甲状腺乳头状癌复发危险程度的分子生物学标记。
Abstract：Objective To investigate gene mutation in correlation with clinical pathological factors in 192 cases of papillary thyroid carcinoma BRAFV600E.Methods Clinical and pathological data were collected,BRAFV600Egene mutation expression analysis of 192 cases of thyroid papillary carcinoma paraffin resectionwas detectedby real time quantitative PCR.The relationship between gene mutation and clinical pathological factors was analyzed.Results The BRAFV600Egene mutation rate of 192 cases papillary thyroid carcinoma was 85.42%(164/192).The BRAFV600Egene mutation rate in papillary microcarcinoma group was83.1%(108/130),BRAFV600Emutation rate in the central lymph node metastasis group was 92.3%(84/91),and BRAFV600Emutation rate in the membrane invasion group was 90%(36/40),BRAFV600Emutation rate in the multifocal group was 67.57%(50/74).BRAFV600Egene mutation hadsignificantly correlation with lymph node metastasis of papillary microcarcinoma,and membrane invasion and multifocal.Conclusion BRAFV600Egene mutations associated with thyroid cancer,can be used as a molecular marker to determine papillary thyroid cancer recurrence risk degree.
[1]ROSIGNOLO F,MAGGISANO V,SPONZIELLO M,et al.Reduced expression of THRβin papillary thyroid carcinomas:relationship with BRAF mutation,aggressiveness and miR expression[J].J Endocrinol Invest,2015,38(12):1283-1289.
[2]高明.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志,2013,33(2):1249-1272.
[3]章阳,崔兆清,孙善平,等.分化型甲状腺癌行颈部淋巴结清扫的意义及方式探讨[J].中国实用外科杂志,2011,31(5):414-416.
[4]爦AHPAZ A,NAL B,YESILYURT A,et al.BRAF(V600E)mutation,RET/PTC1and PAX8-PPAR Gamma rearrangements in follicular epithelium derived thyroid lesions-institutional experience and literature review[J].Balkan Med J,2015,32(2):156-166.
[5]VU-PHAN D,KOENIG R J.Genetics and epigenetics of sporadic thyroid cancer[J].Mol Cell Endocrinol,2014,386(1-2):55-66.
[6]LIU S,ZHANG B,ZHAO Y,et al.Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma:a study on a Chinese population[J].Int J Clin Exp Pathol,2014,7(10):6922-6928.
[7]SHI C,GUO Y,LV Y,et al.Clinicopathological features and prognosis of papillary thyroid microcarcinoma for surgery and relationships with the BRAFV600E mutational status and expression of angiogenic factors[J].PLoS One,2016,11(12):e0167414.
[8]PARK J S,CHANG J W,LIU L,et al.clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma[J].Oral Oncol,2017,72:183-187.
[9]SHI C,QIN H,DING C,et al.Association between BRAF V600Emutation and central lymph node metastasis in patients with papillary thyroid carcinoma[J].Zhonghua Zhong Liu Za Zhi,2015,37(2):123-127.
[10]Ahn D,Park J S,Sohn J H,et al.BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma[J].Auris Nasus Larynx,2012,39(2):198-203.
基本信息:
中图分类号:R736.1
引用信息:
[1]李鸿涛,罗琳,马斌林.192例甲状腺乳头状癌中BRAF~(V600E)基因突变与临床病理因素的关系[J],2018,41(02):221-224.
基金信息:
新疆维吾尔自治区自然科学基金(2014211C116)